Efficacy and safety of using Etelcalcetide for controlling secondary hyperparathyroidism

<h3>Background</h3><p dir="ltr">In Qatar, secondary hyperparathyroidism (SHPT) is a common problem in haemodialysis (HD) patients, associated with significant clinical consequences for Chronic Kidney Disease (CKD) patients, including osteitis fibrosa cystica and calcific...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Tarek Fouda (18472476) (author)
مؤلفون آخرون:	Anees Jamil (18505330) (author), Alaa Ibrahim (7401809) (author), Sahar Aly (6374201) (author), Samah Saeed (18505333) (author), Abeer Ahmed (448250) (author), Thresiamma Abraham (18505335) (author), Asha Jhadav (18505338) (author), Leila Mougou (18505341) (author), Montasser Eloueti (18505343) (author), Nahid Ibrahim (18505344) (author), Rania A/Aziz (18472470) (author), Reema Patrao (18505345) (author), Teha Al Mohannadi (18505348) (author), Wafa Ali (18505349) (author), Karima Ahmed (18505351) (author), Shaza Yousif (18505354) (author), Fadwa Al Ali (18505356) (author), Tarek Ghonimi (16986138) (author), Mohamed Al Kadi (18505359) (author), Abdulah Hamad (18505361) (author), Hassan Al Malki (18505362) (author)
منشور في:	2024
الموضوعات:	Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Health sciences Health services and systems Dialysis Calcimimetic agent Hyperparathyroidism Etelcalcetide Phosphate binders Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Efficacy and safety of using Etelcalcetide for controlling secondary hyperparathyroidism

مواد مشابهة